Profound clinical benefit in a patient with severe, transfusion-refractory anemia treated with GBT440 through Compassionate Use

Lanetta Bronté, M.D.
Foundation for Sickle Cell Disease Research
Hollywood, FL
Disclosures

None
Presentation Overview

- Investigation of treatment options for patients with sickle cell is expanding after years of stagnation
- Unfortunately, options remain limited for patients with severe disease, including those with extreme anemia refractory to transfusion
- We report the experience of a patient treated for over 66 weeks with GBT440*, obtained for compassionate use from Global Blood Therapeutics, Inc., (GBT) the longest exposure to GBT440 of any patient to date

*GBT is an investigational drug for treatment of sickle cell disease and is not approved for patient use by the FDA or any other Regulatory Authority
GBT440- Background

• GBT440 is an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, thereby inhibiting hemoglobin polymerization in sickle cell disease

• HbS polymerization is the trigger that initiates the cascade of events leading to all clinical problems in sickle cell disease including vaso-occlusive pain and anemia

• By inhibiting HbS polymerization, GBT440 is expected to reduce or prevent the clinical manifestations of sickle cell disease

• This hypothesis is being tested in the HOPE Phase 3 trial of GBT440 safety and efficacy
GBT440 Inhibits HbS polymerization, the fundamental cause of clinical injury in sickle cell disease
Patient History

- 67 y.o. man with HbSS disease and multiple RBC alloantibodies that prevent transfusion
- Clinical characteristics include:
  - Hb decline to the range of ~4.5 to 6 g/dL over recent years
  - eGFR stable in the 70 to 75 cc/mm/1.73 m² range
  - Chronic supplemental oxygen therapy for moderate COPD. Room air resting blood O₂ saturations in the range of 90 to 91 mmHg
  - Recurrent, frequent pain exacerbations
  - Extreme fatigue and lethargy
- Ineligible for HOPE trial due to clinical severity including extreme anemia
- GBT440 was provided through single-patient compassionate access by the Sponsor (GBT)
Patient Response to GBT440

- Symptom improvement in 1 to 2 weeks
- Sustained hemoglobin rise ~ 1 to 1.5 g/dL over baseline
- Reticulocytes reduced consistently from baseline
- Indirect bilirubin: Baseline 2.4 mg/dL, 66 weeks 1.6 mg/dL
Patient Response to GBT440 (cont.)

- Sustained improved RA resting $O_2$ saturations (91 mmHg baseline; 96 mmHg week 65)
- Sustained improved RA $O_2$ saturation after six-minute walk test
- Oxygen independent during the day
- Only hospitalization for pain came after motor vehicle accident
- Improved Patient Health Quality-9 (PHQ-9) score consistent with improved mental status
- Quality of life substantially improved
  - Back to driving on his own and able to travel
  - Friends described him as “back to his old self”
  - Self-description of life quality: “excellent,” “great”

### Room Air O2 sat after 6-minute walk test

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 20</th>
<th>Week 65</th>
</tr>
</thead>
<tbody>
<tr>
<td>$O_2$ Sat</td>
<td>86</td>
<td>93</td>
<td>96</td>
</tr>
<tr>
<td>Pulse</td>
<td>102</td>
<td>96</td>
<td>93</td>
</tr>
</tbody>
</table>

### PHQ-9 Score

Weeks of Treatment

0 4 19 46
Adverse Events

• No serious adverse events occurred with GBT440 treatment

• August 2016: Patient clinically stable.
  • GBT440 dose was increased from 900 mg to 1500 mg to boost the percent HbS modification

• Grade 2 diarrhea developed after several days at 1500mg. The diarrhea resolved with return to the 900 mg dose

• No other grade 1/2 adverse events have been observed through month 17
Conclusions

- GBT440 administered through the compassionate use program produced substantial clinical benefits in this single patient who did not qualify for the HOPE trial due to disease severity.
- Clinical benefits were both objective (e.g., sustained rise in hemoglobin) and subjective (less depression as assessed by PHQ-9).
- GBT440 has now been well-tolerated for more than 66 weeks.
- These data provide encouraging evidence of the potential benefit of GBT440 in a broad range of patients.
- Controlled clinical trials will be needed to assess possible GBT440 benefit in other patients with severe anemia.
Questions?